MOXI: Males, Antioxidants, and Infertility

MOXI: Males, Antioxidants, and Infertility

Brief description of study

MOXI is a research study to examine whether antioxidants can improve abnormal semen parameters in couples with male-factor infertility. Eligible male participants will be randomized to either an antioxidant supplement or placebo for 3 months, followed by fertility treatment with ovarian stimulation and intrauterine insemination.

Detailed description of study

MOXI Phase I will involve randomization to either an antioxidant supplement or placebo. This study is blinded, such that neither the participant nor the study team will know which treatment is assigned. After 3 months of treatment (with the assigned study drug), couples will be receive up to 3 consecutive cycles of female ovarian stimulation with an oral medication (clomiphene citrate), triggered ovulation with hCG, and a single intrauterine insemination (Phase II). Couples who conceive in either Phase I or Phase II will be followed through pregnancy and delivery. Male subjects will take their assigned study drug for at least 3 and up to 6 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Male Infertility
  • Age: Between 18 Years - 100 Years
  • Gender: Male


Updated on 09 Aug 2022. Study ID: 821457

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center